Lin BioScience, Inc. (TPEX:6696)

Taiwan · Delayed Price · Currency is TWD

157.50

+1.00 (0.64%)

Oct 28, 2026, 2:00 PM CST

Lin BioScience Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Income	-3,970	-2,857	-1,458	-1,097	-445.13	-338.28
Net Income	-1,609	-1,363	-744.27	-687.19	-313.52	-434.7
Earnings Per Share	-1.94	-1.66	-0.95	-0.93	-0.44	-0.63
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	16,597	16,293	5,208	3,261	1,645	806.85
Total Debt	92.72	22.81	33.99	42.87	46.5	2.24
Net Cash (Debt)	16,505	16,270	5,174	3,218	1,599	804.61
Net Cash Growth	1.44%	214.43%	60.78%	101.30%	98.70%	-25.99%
Net Cash Per Share	19.93	19.82	6.58	4.35	2.23	1.17

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-2,265	-1,441	-1,019	-1,013	-361.01	-289.84
Capital Expenditures	-26.09	-7.2	-5.82	-1.97	-22.38	-2.12
Free Cash Flow	-2,291	-1,449	-1,025	-1,015	-383.4	-291.96
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-	-	-	-	-	-
Operating Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
FCF Margin	-	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.